SR-1375 is under clinical development by Shanghai SIMR Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.
Broncho-Vaxom is under clinical development by OM Pharma and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success ...
The elderly are more susceptible to pneumonia than younger populations. The prevalence of both disability and comorbid diseases increase with age and are associated with increased risk of pneumonia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback